Vaxart company info

What does Vaxart do?
Vaxart (NASDAQ:VXRT) is a biotechnology company focused on developing oral recombinant vaccines based on its proprietary delivery platform. Vaxart's vaccine candidates target a variety of infectious diseases including influenza, norovirus, and coronavirus (COVID-19), aiming to offer an alternative to traditional injection-based vaccines through their tablet formulations. This innovative approach seeks not only to improve the ease of administration but also to enhance patient compliance and potentially broaden vaccine coverage globally. With a commitment to public health, Vaxart’s projects are geared towards producing effective, accessible, and convenient vaccine options. Their objectives center on advancing the clinical development of their vaccine candidates, expanding their vaccine portfolio, and making a significant impact on preventing infectious diseases.
Vaxart company media
Company Snapshot

Is Vaxart a public or private company?

key
Ownership
Public

How many people does Vaxart employ?

people
Employees
109

What sector is Vaxart in?

pie chart
Sector
Health Care

Where is the head office for Vaxart?

location pin
Head Office
South San Francisco, United States

What year was Vaxart founded?

founded flag
Year Founded
2004
What does Vaxart specialise in?
/Oral Vaccines /Clinical Tests /Therapeutic Development /Pandemic Response /Vaccine Tablet /Biotechnology Firm

What are the products and/or services of Vaxart?

Overview of Vaxart offerings
Oral vaccine candidates for COVID-19 aim to provide immunity against SARS-CoV-2 through a convenient tablet form.
Development of a norovirus vaccine tablet targets the prevention of this leading cause of gastroenteritis globally.
Oral influenza vaccine candidate designed to offer an alternative to injected flu vaccines, potentially improving vaccination rates.
An oral human papillomavirus (HPV) vaccine in preclinical stages to provide a non-invasive vaccination option against HPV infections.
Research on a coronavirus oral vaccine tablet, focusing on broad-spectrum protection against multiple coronavirus strains.
Initiating studies for an oral RSV vaccine, targeting the respiratory syncytial virus to offer a needle-free vaccination alternative.

Who is in the executive team of Vaxart?

Vaxart leadership team
  • Dr. Sean N. Tucker Ph.D.
    Dr. Sean N. Tucker Ph.D.
    Senior VP & Chief Scientific Officer
  • Dr. James F. Cummings M.D.
    Dr. James F. Cummings M.D.
    Chief Medical Officer
  • Mr. Steven  Lo
    Mr. Steven Lo
    President, CEO & Director
  • Mr. Phillip Eric  Lee
    Mr. Phillip Eric Lee
    CFO, Principal Financial Officer & Principal Accounting Officer
  • Dr. Raymond D. Stapleton Jr., Ph.D.
    Dr. Raymond D. Stapleton Jr., Ph.D.
    Chief Technology Officer
  • Mr. Edward B. Berg
    Mr. Edward B. Berg
    Senior VP & General Counsel
  • Ms. Shaily Jaini Garg
    Ms. Shaily Jaini Garg
    Senior Vice President of Clinical Development & Project Management
  • Dr. Rajesh  Kapoor Ph.D.
    Dr. Rajesh Kapoor Ph.D.
    Senior Vice President of Quality